Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02039557 · ClinicalTrials.gov registry record
Long Term Follow Up Protocol for NiCord®/CordIn™ (Omidubicel) Patients
A clinical trial, sponsored by Gamida Cell.
- Completed
- Registry status
- 33
- Enrollment target
NCT02039557: Completed study, sponsored by Gamida Cell.
NCT02039557 is a clinical trial that has completed, run by Gamida Cell. The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02039557 has completed, sponsored by Gamida Cell.
- COMPLETED
- Registry status
- 33 participants
- Enrollment target
Study Summary
This is an observational study that will monitor clinical outcomes of patients who have received a NiCord®/CordIn™ (omidubicel) transplant as part of a GC clinical interventional study and meet the eligibility criteria for this Long Term Follow Up study.
Interventions
- GENETIC NiCord®/CordIn™ (omidubicel)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2014-05-01 |
| Est. Completion | 2023-06-29 |
What the finished NCT02039557 record still lists
NCT02039557 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 33 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which NiCord®/CordIn™ (omidubicel) is the first listed.
NCT02039557 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02039557 about?
NCT02039557 is a clinical study titled "Long Term Follow Up Protocol for NiCord®/CordIn™ (Omidubicel) Patients". This is an observational study that will monitor clinical outcomes of patients who have received a NiCord®/CordIn™ (omidubicel) transplant as part of a GC clinical interventional study and meet the eligibility criteria for this Long Term Follow Up study.
What is the current status of trial NCT02039557?
This trial is currently completed. The enrollment target is 33 participants. The study started on 2014-05-01. Estimated completion is 2023-06-29.
What interventions are being tested in trial NCT02039557?
The interventions under investigation include: NiCord®/CordIn™ (omidubicel) (GENETIC).
Who is sponsoring clinical trial NCT02039557?
This trial is sponsored by Gamida Cell, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI